Brii Biosciences is an American biotechnology company based in San Francisco, California.
COVID-19
Several senior representatives of Brii Biosciences participated in the TRACE Working Group of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.[1]
Organization
| Name | Position | Notes |
|---|---|---|
| Lorraine Horgan | Vice President, Program Management | - |
| David Margolis | Vice President, Head of Infectious Diseases Therapy Area | - |
| Li Yan | Chief Medical Officer | - |
| Qing Zhu | Senior Vice President | - |
Partners
Brii Biosciences is partnered with:[2]
- AN2 Therapeutics
- Beijing-Tsinghua Industrial R&D Institute (BTIRDI)
- Columbia University
- Qpex Biopharma
- Third People's Hospital of Shenzhen
- Tsinghua University School of Medicine
- VBI Vaccines
- Vir Biotechnology
- WuXi AppTec
- WuXi Biologics
External links
TRACE Working Group. (2021, June 21). National Institutes of Health (NIH). http://archive.today/2023.07.03-055149/https://www.nih.gov/research-training/medical-research-initiatives/activ/trace-working-group ↩︎
Pipeline. Brii Biosciences. Retrieved July 10, 2023, from http://archive.today/2023.07.10-155412/https://www.briibio.com/en/science/pipeline/ ↩︎
